1 – 100 of 135
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
- Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
- Detecting deviations from the efficacy and safety results of single-arm trials using real-world data : The case of a CAR-T cell therapy in B-cell lymphoma
- Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
- How should we use ibrutinib in patients with mantle cell lymphoma?
- Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
- 2020
- Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition
- p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
- Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
-
National e-library for standardized chemotherapy regimens
Fyhr, Ann Sofie LU ; Borell, Jonas LU
; Jerkeman, Mats
LU
and Ek, Åsa
LU
(2020)
In Acta Oncologica
59(9).
p.1079-1083
Mark
- Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
- Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study
- Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women
- An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement
- Association between anthropometry and lifestyle factors and risk of B-cell lymphoma : An exposome-wide analysis
- Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
- Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study
- 2019
- Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
- Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
- Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
- Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas
- Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition
- Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
- Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
- Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
- Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
- 2018
- Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
- Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
- Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
- Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : A multicentre, open-label, single-arm, phase 2 trial
- Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
- Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
- A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
- Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
- Body composition measurements and risk of hematological malignancies : A population-based cohort study during 20 years of followup
- Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
- Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
- 2017
- Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
- Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
- Newly diagnosed and relapsed mantle cell lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
- TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
- International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
- The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study
- Targeting of B-cell receptor signalling in B-cell malignancies
- Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
- Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
- 2016
- No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
- Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
- Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
- Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration
- Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
- 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
-
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
Pauly, F. LU ; Fjordén, K. LU ; Leppä, S. ; Holte, H. ; Björkholm, M. ; Fluge ; Møller Pedersen, L. ; Eriksson, M. LU
; Isinger-Ekstrand, A.
LU
and Borrebaeck, C. A.K.
LU
, et al.
(2016)
In Blood Cancer Journal
6(11).
p.501-501
Mark
- 2015
- Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
- Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment
- Emerging role of SOX11 in mantle cell lymphoma
- Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.
- Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network
- The impact of age on survival of diffuse large B-cell lymphoma - a population-based study
- Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
- Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.
- Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009 - trends in cure proportions by clinical characteristics.
- Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.
- miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
- Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.
- Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time-a population-based comparative study
- Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials.
- Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
- Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan-two case studies.
- 2014
- Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry
- High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
- Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study
- Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma.
-
Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays.
Pauly, Frida LU ; Smedby, Karin E ; Jerkeman, Mats LU ; Hjalgrim, Henrik ; Ohlsson, Mattias LU
; Rosenquist, Richard
; Borrebaeck, Carl A K
and Wingren, Christer
LU
(2014)
In Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
38(6).
p.682-690
Mark
- Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
- SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.
- Nordic MCL3 study: Y-90-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
- Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
- 2013
- Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
- Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
- 2012
- Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma
-
Expanded clinical and experimental use of SOX11-using a monoclonal antibody
Nordström, Lena LU ; Andreasson, Ulrika LU
; Jerkeman, Mats
LU
; Dictor, Michael
LU
; Borrebaeck, Carl
LU
and Ek, Sara
LU
(2012)
In BMC Cancer
12(269).
Mark
-
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Riihijarvi, Sari ; Nurmi, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Fjordén, Karin LU ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2012)
In European Journal of Haematology
89(5).
p.395-402
Mark
-
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Jerkeman, Mats LU ; Raty, Riikka ; Andersen, Niels S. ; Pedersen, Lone B. ; Eriksson, Mikael LU
; Nordstrom, Marie
and Kimby, Eva
, et al.
(2012)
In British Journal of Haematology
158(3).
p.355-362
Mark
- 2011
- Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study.
- Population-Based Study of Treatment Guided by Tumor Marker Decline in Patients With Metastatic Nonseminomatous Germ Cell Tumor: A Report From the Swedish-Norwegian Testicular Cancer Group.
-
Nordic MCL2 Trial of 1St-Line Intensive Immunochemotherapy and Autologous Stem Cell Transplantation in Mantle Cell Lymphoma: Still Encouraging Results After Median 5½ Years Observation Time
Geisler, C. H. ; Kolstad, A. ; Laurell, A. ; Raty, R. ; Jerkeman, Mats LU ; Eriksson, Mikael LU
; Nordstrom, M.
; Kimby, E.
; Bentzen, H. E. N.
and Nilsson-Ehle, H.
, et al.
(2011)
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation(BMT) Tandem
In Biology of Blood and Marrow Transplantation
17(2).
p.196-196
Mark
- Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
- Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
- Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
- 2010
- Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose Dense Chemoimmuno therapy and CNS Prophylaxis Results From a Nordic Lymphoma Group Phase II Study
-
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Raty, Riikka ; Jerkeman, Mats LU ; Eriksson, Mikael LU
; Nordstrom, Marie
; Kimby, Eva
; Boesen, Anne Marie
and Nilsson-Ehle, Herman
, et al.
(2010)
In Blood
115(8).
p.1530-1533
Mark
- Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
- Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
-
High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study
Riihuarvi, Sari ; Nyman, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2010)
52nd Annual Meeting of the American-Society-of-Hematology (ASH)
In Blood
116(21).
p.1686-1686
Mark
-
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
Andreasson, Ulrika LU
; Edén, Patrik
LU
; Peterson, Carsten
LU
; Högerkorp, Carl-Magnus
LU
; Jerkeman, Mats
LU
; Andersen, Niels
; Berglund, Mattias
; Sundström, Christer
; Rosenquist, Richard
and Borrebaeck, Carl
LU
, et al.
(2010)
In American Journal of Hematology
85(6).
p.418-425
Mark
- SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies